Literature DB >> 34201587

Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library.

Prabhat Pratap Singh Tomar1, Miriam Krugliak1, Isaiah T Arkin1.   

Abstract

SARS-CoV-2, the etiological agent of the COVID-19 pandemic, is a member of the Coronaviridae family. It is an enveloped virus with ion channels in its membrane, the most characterized of which is the E protein. Therefore, in an attempt to identify blockers of the E channel, we screened a library of 2839 approved-for-human-use drugs. Our approach yielded eight compounds that exhibited appreciable activity in three bacteria-based channel assays. Considering the fact that the E channel is the most conserved of all SARS-CoV-2 proteins, any inhibitor of its activity may provide an option to curb the viral spread. In addition, inhibitors can also enhance our ability to understand the exact role played by the E protein during the infectivity cycle. Finally, detailed electrophysiological analyses, alongside in vitro and in vivo studies will be needed to establish the exact potential of each of the blockers identified in our study.

Entities:  

Keywords:  COVID-19; antiviral drugs; bacterial assays; channel blockers; viral channels

Year:  2021        PMID: 34201587     DOI: 10.3390/ph14070604

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  41 in total

1.  Quantitative analysis of influenza M2 channel blockers.

Authors:  Peleg Astrahan; Ravenna Flitman-Tene; Estelle R Bennett; Miriam Krugliak; Chaim Gilon; Isaiah T Arkin
Journal:  Biochim Biophys Acta       Date:  2010-09-08

2.  Computational and experimental analysis of drug binding to the Influenza M2 channel.

Authors:  Raphael Alhadeff; Dror Assa; Peleg Astrahan; Miriam Krugliak; Isaiah T Arkin
Journal:  Biochim Biophys Acta       Date:  2013-09-07

3.  Requirement of a large K+-uptake capacity and of extracytoplasmic protease activity for protamine resistance of Escherichia coli.

Authors:  S Stumpe; E P Bakker
Journal:  Arch Microbiol       Date:  1997 Feb-Mar       Impact factor: 2.552

4.  A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo.

Authors:  Marta L DeDiego; Enrique Alvarez; Fernando Almazán; María Teresa Rejas; Elaine Lamirande; Anjeanette Roberts; Wun-Ju Shieh; Sherif R Zaki; Kanta Subbarao; Luis Enjuanes
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

5.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

6.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

7.  MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels.

Authors:  Wahyu Surya; Yan Li; Carmina Verdià-Bàguena; Vicente M Aguilella; Jaume Torres
Journal:  Virus Res       Date:  2015-02-27       Impact factor: 3.303

8.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

9.  An interactive web-based dashboard to track COVID-19 in real time.

Authors:  Ensheng Dong; Hongru Du; Lauren Gardner
Journal:  Lancet Infect Dis       Date:  2020-02-19       Impact factor: 25.071

View more
  4 in total

1.  Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2.

Authors:  Anamika Singh; Isaiah T Arkin
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

Review 2.  Traditional Uses, Pharmacological Effects, and Molecular Mechanisms of Licorice in Potential Therapy of COVID-19.

Authors:  Qian-Hui Zhang; Hao-Zhou Huang; Min Qiu; Zhen-Feng Wu; Zhan-Chang Xin; Xin-Fu Cai; Qiang Shang; Jun-Zhi Lin; Ding-Kun Zhang; Li Han
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

3.  Searching for Blockers of Dengue and West Nile Virus Viroporins.

Authors:  Hiya Lahiri; Isaiah T Arkin
Journal:  Viruses       Date:  2022-08-11       Impact factor: 5.818

4.  Zika M-A Potential Viroporin: Mutational Study and Drug Repurposing.

Authors:  Prabhat Pratap Singh Tomar; Miriam Krugliak; Anamika Singh; Isaiah T Arkin
Journal:  Biomedicines       Date:  2022-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.